Reports
Sale
Australia and New Zealand Anemia in Pregnancy Market Size: By Cause: Folic Acid Deficiency, Iron Deficiency, Vitamin B12 Deficiency, Others; By Treatment: Iron Products, Folic Acid Supplementation, Others; By Weeks; By Route of Administration; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Australia and New Zealand Anemia in Pregnancy Market Outlook
The Australia and New Zealand anemia in pregnancy market size is expected to grow at a CAGR of 8.6% during the forecast period of 2024-2032. The growth of the market is likely to be driven by increasing incidence of pregnancies and rising awareness programs around the condition.
Australia and New Zealand Anemia in Pregnancy Market Overview
On average, the human body requires around five liters of blood. Towards the end of pregnancy, the requirement reaches around seven to eight liters. The body requires about thrice as much iron during pregnancy, and when the requirement is not met promptly, women tend to develop anemia. Approximately 40% of women begin their pregnancy with depleted iron levels in the body. Folate (folic acid) and vitamin B12 deficiency, pre-eclampsia and sickle cell disease can also lead to anemia in pregnancy.
Australia and New Zealand anemia in pregnancy market demand is driven by growing focus on alleviating pregnancy complications in both the mother as well as the fetus. Anemia is associated with growth in cesarean delivery, postpartum depression, perinatal blood transfusion and even low birth weight, and preterm birth in neonates as well. Low iron levels are also linked neurological impairments that may persist even in adulthood. Hence, there has been significant emphasis on treating anemia in pregnancy.
The market is driven by rising initiatives to spread awareness around the condition, along with growth in research and development activities to develop enhanced and diverse alternatives for patients.
Research Activities to Develop Safe Alternatives to Contribute to the Australia and New Zealand Anemia in Pregnancy Market Share
Dietary iron is often hard to absorb in the body, thus, it can be difficult to uptake sufficient iron content from the food sources a person consumes. To offer improved alternatives to patients, scientists have been exploring new and innovative methods in different routes of administration. To treat anemia associated with inflammatory bowel disease in pregnancy, a study presented at United European Gastroenterology Week 2023 demonstrated positive effects of ferric maltol. Administered in 27 pregnant women expecting to give birth in April or May 2023, the drug proceeded without complications and led to birth of healthy infants except for 2 patients.
Iron supplementation is one of the most common and recommended treatment methods for anemia in pregnancy. For high doses, oral iron (ferrous sulphate) is the current standard treatment, owing effective, inexpensive, and readily available concentration. However, higher, and frequent dosage has led to gastrointestinal perturbation, resulting in decreased adherence to therapy. As a result, research activities for alternative therapies have been on the rise. Intravenous iron therapy is emerging as a significant option, especially for catering women in their second or third trimesters. Low-molecular weight iron dextran, ferric derisomaltose, or ferric carboxymaltose are commonly preferred for intravenous therapies. Increasing advancements in biotechnology domain are poised to boost the Australia and New Zealand anemia in pregnancy market growth in the coming years.
Rise in Initiatives to Spread Awareness
A survey conducted in November 2023 revealed that most Australians (24%) were unaware or had limited information of common iron deficiency related symptoms. Around 90% of them were unaware of ice cravings, dizziness (57%) and shortness of breath (81%). Therefore, there has been significant emphasis on educating the public, particularly pregnant women, to combat the repercussions that may align with the deficiency. ‘Take Iron Seriously’ is an awareness campaign launched to offer information to easily detect the condition on early stages so as to facilitate appropriate treatment in due time. The increasing arrangement of such programs is anticipated to drive the market growth during the forecast period.
Australia and New Zealand Anemia in Pregnancy Market Segmentation
Market Breakup by Cause
- Folic Acid Deficiency
- Iron Deficiency
- Vitamin B12 Deficiency
- Others
Market Breakup by Treatment
- Iron Products
- Folic Acid Supplementation
- Others
Market Breakup by Weeks
- < 13 Weeks
- 13-27 Weeks
- ≥28 Weeks
Market Breakup by Route of Administration
- Oral
- Intravenous
- Intramuscular
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by End User
- Hospitals
- Specialty Clinics
- Home Healthcare
- Others
Market Breakup by Country
- Australia
- New Zealand
Australia and New Zealand Anemia in Pregnancy Market Regional Analysis
To prevent mortalities associated with anemia, there has been significant emphasis on diagnosing the condition early in pregnancy. Therefore, the region has been witnessing significant development in well-equipped public hospitals and clinics. In the forecast period, Australia is poised to lead the Australia and New Zealand anemia in pregnancy market share, owing to rising prevalence for personalized care.
New Zealand is also poised to witness substantial growth which can be attributed to rising emergence of technology driven start-ups along with increased collaboration between pharmaceutical companies and research institutions.
Australia and New Zealand Anemia in Pregnancy Market: Competitor Landscape
In June 2023, Janssen Pharmaceutical (a division of Johnson & Johnson) announced positive results for Nipocalimab, a drug for treating hemolytic disease of the fetus and newborn (HDFN) in pregnant individual at high risk of developing the condition. The drug is the only therapy for HDFN wherein the foetus may develop anemia due to incompatible blood type with the pregnant individual. It showed promising results in the Phase 2 open-label UNITY clinical trial.
The key features of the Australia and New Zealand anemia in pregnancy market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Viatris Inc.
- Aspen Pharmacare Australia Pty Ltd
- PharmaCare Laboratories Australia
- AFT Pharmaceuticals
- Bayer AG
- A Nelson & Co Ltd
- BLACKMORES
- Care Pharma
- Amgen Inc.
- Hoffmann-La Roche Ltd.
- AMAG Pharmaceuticals
- Rockwell Medical
- Vifor Pharma Management Ltd.
- Janssen Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Cause |
|
| Breakup by Treatment |
|
| Breakup by Weeks |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Australia and New Zealand Anemia in Pregnancy Market Overview
3.1 Australia and New Zealand Anemia in Pregnancy Market Historical Value (2017-2023)
3.2 Australia and New Zealand Anemia in Pregnancy Market Forecast Value (2024-2032)
4 Australia and New Zealand Anemia in Pregnancy Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Australia and New Zealand Anemia in Pregnancy Market Segmentation
5.1 Australia and New Zealand Anemia in Pregnancy Market by Cause
5.1.1 Market Overview
5.1.2 Folic Acid Deficiency
5.1.3 Iron Deficiency
5.1.4 Vitamin B12 Deficiency
5.1.5 Others
5.2 Australia and New Zealand Anemia in Pregnancy Market by Treatment
5.2.1 Market Overview
5.2.2 Iron Products
5.2.3 Folic Acid Supplementation
5.2.4 Others
5.3 Australia and New Zealand Anemia in Pregnancy Market by Weeks
5.3.1 Market Overview
5.3.2 < 13 Weeks
5.3.3 13-27 Weeks
5.3.4 ≥28 Weeks
5.4 Australia and New Zealand Anemia in Pregnancy Market by Route of Administration
5.4.1 Market Overview
5.4.2 Oral
5.4.3 Intravenous
5.4.4 Intramuscular
5.5 Australia and New Zealand Anemia in Pregnancy Market by Distribution Channel
5.5.1 Market Overview
5.5.2 Hospital Pharmacy
5.5.3 Retail Pharmacy
5.5.4 Online Pharmacy
5.5.5 Others
5.6 Australia and New Zealand Anemia in Pregnancy Market by End User
5.6.1 Market Overview
5.6.2 Hospitals
5.6.3 Specialty Clinics
5.6.4 Home Healthcare
5.6.5 Others
5.7 Australia and New Zealand Anemia in Pregnancy Market by Country
5.7.1 Market Overview
5.7.2 Australia
5.7.3 New Zealand
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 Viatris Inc.
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 Aspen Pharmacare Australia Pty Ltd
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 PharmaCare Laboratories Australia
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 AFT Pharmaceuticals
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Bayer AG
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 A Nelson & Co Ltd
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 BLACKMORES
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 Care Pharma
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 Amgen Inc.
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Hoffmann-La Roche Ltd.
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 AMAG Pharmaceuticals
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Rockwell Medical
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
11.13 Vifor Pharma Management Ltd.
11.13.1 Financial Analysis
11.13.2 Product Portfolio
11.13.3 Demographic Reach and Achievements
11.13.4 Mergers and Acquisitions
11.13.5 Certifications
11.14 Janssen Pharmaceuticals, Inc.
11.14.1 Financial Analysis
11.14.2 Product Portfolio
11.14.3 Demographic Reach and Achievements
11.14.4 Mergers and Acquisitions
11.14.5 Certifications
11.15 Teva Pharmaceutical Industries Ltd.
11.15.1 Financial Analysis
11.15.2 Product Portfolio
11.15.3 Demographic Reach and Achievements
11.15.4 Mergers and Acquisitions
11.15.5 Certifications
12 Australia and New Zealand Anemia in Pregnancy Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 8.6% during the forecast period of 2024-2032, likely to be driven by rising incidence of pregnancies across the region.
The market demand is driven by increasing prevalence of anemia, focus on spreading appropriate awareness for early diagnosis of the disease and advancements in treatment options.
The growing emphasis on developing safe treatment alternatives that address specific indications in patients is a major market trend. Currently there has been research on using ferric maltol to treat anemia associated with inflammatory bowel disease in pregnancy.
Based on causes, the market is divided into folic acid deficiency, iron deficiency, vitamin b12 deficiency, and others.
Iron products, folic acid supplementation, and others are common treatments available in the market.
It includes less than 13 weeks, 13-27 weeks, and greater than 28 weeks.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
Major end users include hospitals, speciality clinics, home healthcare and others.
The route of administration can be oral, intravenous, and intramuscular.
It is divided into Australia and New Zealand.
Key players involved in the market are Viatris Inc., Aspen Pharmacare Australia Pty Ltd., PharmaCare Laboratories Australia, AFT Pharmaceuticals, Bayer AG, A Nelson & Co Ltd., BLACKMORES, Care Pharma, Amgen Inc., Hoffmann-La Roche Ltd., AMAG Pharmaceuticals, Rockwell Medical, Vifor Pharma Management Ltd., Janssen Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2199
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3299
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4399
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5499
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER